{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:10:02Z","timestamp":1748981402948,"version":"3.41.0"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["opencardiovascularmedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOCMJ"],"published-print":{"date-parts":[[2016,5,27]]},"abstract":"<jats:p>Muscular dystrophy and myasthenia gravis are two neuromuscular disorders that can involve significant cardiovascular complications. The frequency and severity of cardiac pathology varies widely among the muscular dystrophies. In some, it is nearly inevitable and requires regular evaluation. In others, assessment of cardiac function can be more symptom-driven. On-ly a minority of myasthenic patients manifest disease-related cardiovascular complications; however, their presentation can be rapidly progressive and life-threatening..<\/jats:p>","DOI":"10.2174\/1874192401610010082","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T11:23:29Z","timestamp":1464348209000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Overview of Cardiac Management in Neuromuscular Disease"],"prefix":"10.2174","volume":"10","author":[{"given":"Renee M.","family":"Hickey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George M.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.nmd.2010.04.008","volume":"20","author":"Hermans M.C.","year":"2010","unstructured":"Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscul Disord 2010; 20 (8) : 479-92.","journal-title":"Neuromuscul. Disord."},{"key":"refR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/qjmed\/hcm124","volume":"101","author":"Beynon R.P.","year":"2008","unstructured":"Beynon RP, Ray SG. Cardiac involvement in muscular dystrophies. QJM 2008; 101 (5) : 337-44.","journal-title":"QJM"},{"key":"refR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.pmr.2012.08.001","volume":"23","author":"Allen H.D.","year":"2012","unstructured":"Allen HD, Thrush PT, Hoffman TM, Flanigan KM, Mendell JR. Cardiac management in neuromuscular diseases. Phys Med Rehabil Clin N Am 2012; 23 (4) : 855-68.","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"refR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.22097","volume":"44","author":"Spurney C.F.","year":"2011","unstructured":"Spurney CF. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 2011; 44 (1) : 8-19.","journal-title":"Muscle Nerve"},{"key":"refR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.prrv.2009.10.004","volume":"11","author":"Hsu D.T.","year":"2010","unstructured":"Hsu DT. Cardiac manifestations of neuromuscular disorders in children. Paediatr Respir Rev 2010; 11 (1) : 35-8.","journal-title":"Paediatr. Respir. Rev."},{"key":"refR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","volume":"91","author":"Silversides C.K.","year":"2003","unstructured":"Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003; 91 (6) : 769-72.","journal-title":"Am. J. Cardiol."},{"key":"refR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/heartjnl-2011-300254","volume":"98","author":"Yilmaz A.","year":"2012","unstructured":"Yilmaz A, Sechtem U. Cardiac involvement in muscular dystrophy: advances in diagnosis and therapy. Heart 2012; 98 (5) : 420-9.","journal-title":"Heart"},{"key":"refR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ahj.2007.05.014","volume":"154","author":"Duboc D.","year":"2007","unstructured":"Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years\u2019 follow-up. Am Heart J 2007; 154 (3) : 596-602.","journal-title":"Am. Heart J."},{"key":"refR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11897-010-0028-2","volume":"7","author":"Romfh A.","year":"2010","unstructured":"Romfh A, McNally EM. Cardiac assessment in duchenne and becker muscular dystrophies. Curr Heart Fail Rep 2010; 7 (4) : 212-8.","journal-title":"Curr. Heart Fail. Rep."},{"key":"refR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/nature03844","volume":"436","author":"Yasuda S.","year":"2005","unstructured":"Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005; 436 (7053) : 1025-9.","journal-title":"Nature"},{"key":"refR11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1172\/JCI41329","volume":"120","author":"Townsend D.","year":"2010","unstructured":"Townsend D, Turner I, Yasuda S, et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010; 120 (4) : 1140-50.","journal-title":"J. Clin. Invest."},{"key":"refR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/heart.87.4.346","volume":"87","author":"Hausse A.O.","year":"2002","unstructured":"Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich\u2019s ataxia. Heart 2002; 87 (4) : 346-9.","journal-title":"Heart"},{"key":"refR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","volume":"378","author":"Cirak S.","year":"2011","unstructured":"Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378 (9791) : 595-605.","journal-title":"Lancet"},{"key":"refR14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"Goemans N.M.","year":"2011","unstructured":"Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy. N Engl J Med 2011; 364 (16) : 1513-22.","journal-title":"N. Engl. J. Med."},{"key":"refR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"Bushby K.","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50 (4) : 477-87.","journal-title":"Muscle Nerve"},{"key":"refR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","volume":"21","author":"Suzuki S.","year":"2014","unstructured":"Suzuki S, Baba A, Kaida K, et al. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 2014; 21 (2) : 223-30.","journal-title":"Eur. J. Neurol."},{"key":"refR17","first-page":"597","volume":"20","author":"Weigert C.","year":"1943","unstructured":"Weigert C. Pathogisch-anatomischer Beitrag zur Erb\u2019schen Krankheit (myasthenia gravis). Neurol Zentralbl 1943; 20 : 597.","journal-title":"Neurol Zentralbl"},{"key":"refR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1600-0404.1984.tb00817.x","volume":"70","author":"Hofstad H.","year":"1984","unstructured":"Hofstad H, Ohm OJ, M\u00f8rk SJ, Aarli JA. Heart disease in myasthenia gravis. Acta Neurol Scand 1984; 70 (3) : 176-84.","journal-title":"Acta Neurol. Scand."},{"key":"refR19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3892\/ol.2011.501","volume":"3","author":"Sasaki H.","year":"2012","unstructured":"Sasaki H, Yano M, Kawano O, Hikosaka Y, Fujii Y. Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel: A case report. Oncol Lett 2012; 3 (2) : 300-2.","journal-title":"Oncol. Lett."},{"key":"refR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1440-1789.2012.01345.x","volume":"33","author":"Kon T.","year":"2013","unstructured":"Kon T, Mori F, Tanji K, Miki Y, Kimura T, Wakabayashi K. Giant cell polymyositis and myocarditis associated with myasthenia gravis and thymoma. Neuropathology 2013; 33 (3) : 281-7.","journal-title":"Neuropathology"},{"key":"refR21","doi-asserted-by":"publisher","unstructured":"Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011.","DOI":"10.4061\/2011\/740583"},{"key":"refR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/mus.22220","volume":"44","author":"Bansal V.","year":"2011","unstructured":"Bansal V, Kansal MM, Rowin J. Broken heart syndrome in myasthenia gravis. Muscle Nerve 2011; 44 (6) : 990-3.","journal-title":"Muscle Nerve"},{"key":"refR23","first-page":"207","volume":"44","author":"Arai M.","year":"2004","unstructured":"Arai M, Ukigai H, Miyata H. A case of transient left ventricular ballooning (\u201cTakotsubo\u201d-shaped cardiomyopathy) developed during plasmapheresis for treatment of myasthenic crisis. Rinsho Shinkeigaku 2004; 44 (3) : 207-10.","journal-title":"Rinsho Shinkeigaku"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.33588\/rn.5512.2012465","volume":"55","author":"Mayor-Gomez S.","year":"2012","unstructured":"Mayor-Gomez S, Lacruz F, Ezpeleta D. Myasthenic crisis and Takotsubo syndrome: a non-chance relationship. Rev Neurol 2012; 55 (12) : 725-8.","journal-title":"Rev. Neurol."},{"key":"refR25","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1540-8191.2010.01093.x","volume":"25","author":"Antevil J.L.","year":"2010","unstructured":"Antevil JL, Carroll CG, Roberts PF, Johnston MG, Strange RG. Myasthenia gravis-an unexpected cause of respiratory failure and reversible left ventricular dysfunction after cardiac surgery. J Card Surg 2010; 25 (6) : 662-4.","journal-title":"J. Card. Surg."},{"key":"refR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clineuro.2012.05.013","volume":"115","author":"Shukla G.","year":"2013","unstructured":"Shukla G, Gupta S, Goyal V, Singh S, Srivastava A, Behari M. Abnormal sympathetic hyper-reactivity in patients with myasthenia gravis: a prospective study. Clin Neurol Neurosurg 2013; 115 (2) : 179-86.","journal-title":"Clin. Neurol. Neurosurg."},{"key":"refR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1600-0404.1984.tb00817.x","volume":"70","author":"Hofstad H.","year":"1984","unstructured":"Hofstad H, Ohm OJ, M\u00f8rk SJ, Aarli JA. Heart disease in myasthenia gravis. Acta Neurol Scand 1984; 70 (3) : 176-84.","journal-title":"Acta Neurol. Scand."},{"key":"refR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1566-0702(01)00239-9","volume":"88","author":"Vernino S.","year":"2001","unstructured":"Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 2001; 88 (3) : 187-92.","journal-title":"Auton. Neurosci."}],"container-title":["The Open Cardiovascular Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V10\/TOCMJ-10-82\/TOCMJ-10-82.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V10\/TOCMJ-10-82\/TOCMJ-10-82.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V10\/TOCMJ-10-82\/TOCMJ-10-82.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:47:10Z","timestamp":1748980030000},"score":1,"resource":{"primary":{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/VOLUME\/10\/PAGE\/82\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,5,27]]}},"alternative-id":["TOCMJ-10-82"],"URL":"https:\/\/doi.org\/10.2174\/1874192401610010082","relation":{},"ISSN":["1874-1924"],"issn-type":[{"type":"print","value":"1874-1924"}],"subject":[],"published":{"date-parts":[[2016,5,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2015-9-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}